Lonza Group: Transition to a focused CDMO, with robust demand and disciplined growth, underpins a positive outlook
Strong demand from pharma and biotech supports a positive outlook, with a strategic shift to a pure-play CDMO and disciplined M&A. Specialized Modalities rebounded in 2026, while Integrated Biologics growth aligns with capacity expansion plans. Margin and cash flow improvements are targeted through…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.